AI-driven approaches in therapeutic interventions: Transforming RNA-seq analysis into biomarker discovery and drug development

IF 7.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Discovery Today Pub Date : 2025-05-29 DOI:10.1016/j.drudis.2025.104391

Zehra , Anam Bakhtiyar , Asimul Islam , Romana Ishrat , Md. Imtaiyaz Hassan

{"title":"AI-driven approaches in therapeutic interventions: Transforming RNA-seq analysis into biomarker discovery and drug development","authors":"Zehra , Anam Bakhtiyar , Asimul Islam , Romana Ishrat , Md. Imtaiyaz Hassan","doi":"10.1016/j.drudis.2025.104391","DOIUrl":null,"url":null,"abstract":"<div><div>Pharmacotranscriptomics integrates transcriptomics and pharmacology to discover potential therapeutic targets for effective treatment. This review focuses on significant advancements in combining artificial intelligence (AI) with transcriptomic research, enabling the conversion of vast data sets into valuable knowledge for for developing effective therapeutics. We provide detailed insights into implementing machine learning (ML) techniques for analyzing intricate transcriptomic data, facilitating a comprehensive understanding of disease mechanisms and the identification of key signature genes for biomarker and drug development. We further highlighted the potential of ML to streamline the drug discovery process by revealing disease mechanisms and suggesting therapeutic interventions. This review presents a comprehensive framework of AI models and their applications within pharmacotranscriptomics analysis. We also discuss the challenges and limitations needed to optimize AI models for enhanced therapeutic outcomes.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 7","pages":"Article 104391"},"PeriodicalIF":7.5000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359644625001047","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Pharmacotranscriptomics integrates transcriptomics and pharmacology to discover potential therapeutic targets for effective treatment. This review focuses on significant advancements in combining artificial intelligence (AI) with transcriptomic research, enabling the conversion of vast data sets into valuable knowledge for for developing effective therapeutics. We provide detailed insights into implementing machine learning (ML) techniques for analyzing intricate transcriptomic data, facilitating a comprehensive understanding of disease mechanisms and the identification of key signature genes for biomarker and drug development. We further highlighted the potential of ML to streamline the drug discovery process by revealing disease mechanisms and suggesting therapeutic interventions. This review presents a comprehensive framework of AI models and their applications within pharmacotranscriptomics analysis. We also discuss the challenges and limitations needed to optimize AI models for enhanced therapeutic outcomes.

查看原文本刊更多论文

人工智能驱动的治疗干预方法：将RNA-seq分析转化为生物标志物发现和药物开发。

药物转录组学将转录组学和药理学结合起来，发现潜在的有效治疗靶点。本文综述了人工智能（AI）与转录组学研究相结合的重大进展，使大量数据集转化为治疗学的有价值知识。我们为实现机器学习（ML）技术分析复杂的转录组学数据提供了详细的见解，促进了对疾病机制的全面理解，并为生物标志物和药物开发确定了关键特征基因。我们进一步强调ML通过揭示疾病机制和提出治疗干预措施来简化药物发现过程的潜力。本文综述了人工智能模型的框架及其在药物转录组学分析中的应用。我们还讨论了优化人工智能模型以提高治疗效果所需的挑战和局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today 医学-药学

CiteScore

14.80

自引率

2.70%

发文量

293

审稿时长

6 months

期刊介绍： Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.